Partnership combines enterprise technology with real-world evidence expertise to maximise the strategic value of Managed Access Programs. 

Maprium, the company behind the Managed Access Operating System, today announced a strategic collaboration with Vitaccess, a patient-centred real-world research consultancy, to help pharmaceutical companies manage global Managed Access Programs (MAPs) while generating high-quality real-world evidence (RWE) through a single, connected approach. 

As MAPs become increasingly strategic, pharmaceutical companies face growing pressure to generate evidence that supports regulatory engagement, market access, reimbursement and future commercial decision-making. Yet program management and evidence generation often remain fragmented across multiple vendors, disconnected systems and manual processes, limiting visibility, increasing complexity and reducing program value. 

The collaboration brings together Maprium's operating system for global program management with Vitaccess' expertise in patient-centred research and regulatory-aligned evidence generation. 

Maprium enables pharmaceutical companies to plan, govern and oversee global MAPs with complete visibility, control and compliance across countries, partners and internal teams. Vitaccess complements this by designing and delivering scientifically robust real-world evidence strategies, including patient-reported outcomes, digital data collection, protocol development and data analysis, ensuring evidence generation is built into programmes from the outset. 

Together, the collaboration enables pharmaceutical companies to: 

• Manage global Managed Access Programs through a single, purpose-built operating system. 

• Embed high-quality, science-led real-world evidence collection into program delivery. 

• Capture patient-reported outcomes and clinically meaningful data using robust methodologies. 

• Generate evidence aligned with regulatory, HTA and reimbursement requirements. 

• Improve governance, visibility and data quality while reducing operational complexity. 

• Maximise program value by combining patient access and evidence generation within one connected ecosystem. 

"MAPs should deliver value far beyond patient access alone.” said Dr Romina Oxborough, CEO of Maprium. “Through this collaboration, pharmaceutical companies can manage programs through a single platform while integrating high-quality evidence generation into routine operations. The result is stronger governance, better insights and greater strategic value from every program." 

Mark Larkin, CEO and Founder of Vitaccess added "Managed Access Programs represent a valuable opportunity to understand how treatments perform in real-world clinical practice. By combining our expertise in patient-centred research with Maprium's operating system, pharmaceutical companies can design evidence generation into programs from the start, ensuring the data collected is scientifically robust and supports future decision-making." 

The collaboration reflects a shared vision to help pharmaceutical companies transform Managed Access Programs into strategic assets by combining operational excellence with integrated evidence generation in a scalable, connected solution that benefits both patients and future access decisions. 

ENDS 

About Maprium 

Maprium is the Managed Access Operating System for BioPharma. Purpose-built by Managed Access experts, Maprium enables pharmaceutical companies to plan, govern and oversee global Managed Access Programs from a single, vendor-agnostic system. 

Combining purpose-built technology with deep Managed Access expertise, Maprium provides greater visibility, control and consistency across programs, partners and geographies. By enabling organizations to retain ownership of their operations and data, Maprium helps transform Managed Access from a fragmented operational activity into a scalable, strategic enterprise capability. 

www.maprium.com 

About Vitaccess  

Vitaccess is a UK-based leader in real-world evidence generation, closing the insight gap for biopharma companies, by putting patient voices at the centre of research that matters. Through scientifically rigorous, expert-led patient research, we deliver the full spectrum of evidence generation, from qualitative concept elicitation through longitudinal registries.  

Vitaccess integrates Electronic Medical Record (EMR) data with patient-reported outcomes, qualitative research, and preference studies, providing nuanced real-world evidence that supports payer and regulatory decision-making, across a range of therapeutic areas including rare diseases, oncology, respiratory, and haematology. 

www.vitaccess.com 

About Managed Access Programs (MAPs) 

Managed Access Programs (MAPs) enable patients with serious or life-threatening conditions to access medicines that are not yet commercially available in their country, where permitted by local regulations. Also known as Early Access, Expanded Access or Compassionate Use, these programs provide a structured pathway to treatment outside clinical trials and routine commercial supply. 

Media Contact 

Angela Norton-Bilsby 

Marketing and Communications, Maprium 

Angela.norton-bilsby@maprium.com 

Tel: (+44) 7795 210003